NEW YORK-- ( BUSINESS WIRE )--Hess Corporation (NYSE: HES) announced today that John Hess, Chief Executive Officer, will ...

Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following ...

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had pressured Regeneron from all-time highs, and the firm ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been and remains the treatment and prevention of HIV and liver ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ:WBD) to Peer Perform from Underperform following its Q3 results last week, and assigned a fair value range of $ ...

On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte's ...